(UroToday.com) Though patients with non-metastatic castration-resistant prostate cancer (nmCRPC) are generally asymptomatic from their cancer, the development of metastatic disease reduces their quality of life for several reasons. Three drugs that target the androgen receptor are approved in nmCRPC and delay time to the development of metastatic disease. However, treatment with these agents is associated with side effects that also reduce quality of life.